Thematics Asset Management Decreases Stock Position in Axon Enterprise, Inc $AXON

Thematics Asset Management trimmed its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 5.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,568 shares of the biotechnology company’s stock after selling 1,524 shares during the quarter. Thematics Asset Management’s holdings in Axon Enterprise were worth $18,349,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $480,000. NewEdge Advisors LLC boosted its stake in Axon Enterprise by 41.1% during the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after buying an additional 668 shares during the last quarter. Empowered Funds LLC grew its holdings in Axon Enterprise by 8.4% in the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after buying an additional 157 shares in the last quarter. Woodline Partners LP increased its stake in shares of Axon Enterprise by 40.6% in the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after acquiring an additional 2,003 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Axon Enterprise in the 2nd quarter worth $284,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the transaction, the insider directly owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. This represents a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total value of $5,002,400.00. Following the sale, the chief executive officer directly owned 3,090,997 shares in the company, valued at $1,546,240,339.28. This trade represents a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 24,634 shares of company stock valued at $13,803,095 in the last ninety days. Insiders own 4.40% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $496.18 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The company has a market cap of $39.89 billion, a price-to-earnings ratio of 326.44, a price-to-earnings-growth ratio of 10.66 and a beta of 1.46. The stock’s 50-day moving average is $531.08 and its two-hundred day moving average is $610.44. Axon Enterprise, Inc has a 1-year low of $396.41 and a 1-year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. During the same period in the previous year, the company posted $2.08 earnings per share. The business’s revenue for the quarter was up 38.5% on a year-over-year basis. Analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AXON. Morgan Stanley decreased their price objective on Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Northcoast Research raised Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a research note on Tuesday, January 6th. Piper Sandler reduced their target price on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Robert W. Baird set a $800.00 price target on Axon Enterprise in a research note on Wednesday, February 25th. Finally, Royal Bank Of Canada lowered their price target on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.